Omnicell (NASDAQ: OMCL) reported Q2 EPS of $0.46, $0.07 better than the analyst estimate of $0.39. Revenue for the quarter came in at $188.7 million versus the consensus estimate of $188.77 million.

Non-GAAP Results

• Non-GAAP revenues for the second quarter of 2018 were $188.7 million, up $7.3 million, or 4.0% from the second quarter of 2017. Non-GAAP revenues for the six months ended June 30, 2018 were $371.3 million, up $41.1 million, or 12.4% from the six months ended June 30, 2017.
• Non-GAAP net income for the second quarter of 2018 was $18.4 million, or $0.46 per diluted share. This compares to non-GAAP net income of $12.8 million, or $0.33 per diluted share, for the second quarter of 2017.
• Non-GAAP net income for the six months ended June 30, 2018 was $29.8 million, or $0.75 per diluted share. This compares to non-GAAP net income of $15.3 million, or $0.40 per diluted share, for the six months ended June 30, 2017.

"Medication management is playing an increasingly strategic role in patient outcomes and the financial success of healthcare institutions," said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. "With a continued focus on digital transformation and strategic partnerships, we are driving efficiency and supporting patient safety through Omnicell\'s industry-leading platform."

GUIDANCE:

Omnicell sees FY2018 EPS of $1.90-$2.05, versus the consensus of $1.95. Omnicell sees FY2018 revenue of $630-665 million, versus the consensus of $790.27 million.

For earnings history and earnings-related data on Omnicell (OMCL) click here.